

L Number	Hits	Search Text	DB	Time stamp
1	0	("514/183,,243,63,408,416,417").CCLS	USPAT	2004/03/12 12:05
2	3709	("514/183,13,243").CCLS	USPAT	2004/03/12 12:06
3	1287	("514/408,416,417").CCLS	USPAT	2004/03/12 12:06
4	704	("548/452,470,472").CCLS	USPAT	2004/03/12 12:07
5	86	("514/183,13,243").CCLS) and ("514/408,416,417").CCLS)	USPAT	2004/03/12 12:10
6	9	("548/452,470,472").CCLS) and (("514/183,13,243").CCLS) and	USPAT	2004/03/12 12:07
7	9	("514/408,416,417").CCLS) and ("514/183,13,243").CCLS) and	USPAT	2004/03/12 12:07
8	11	("548/452,470,472").CCLS) and (("514/183,13,243").CCLS) and	USPAT	2004/03/12 12:10
		("514/408,416,417").CCLS) and ("514/408,416,417").CCLS) and respiratory	USPAT	2004/03/12 12:10

Welcome to STN International! Enter x:x

LOGINID:sssptal611sxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 09	CA/CAPLUS records now contain indexing from 1907 to the present
NEWS	4	DEC 08	INPADOC: Legal Status data reloaded
NEWS	5	SEP 29	DISSABS now available on STN
NEWS	6	OCT 10	PCTFULL: Two new display fields added
NEWS	7	OCT 21	BIOSIS file reloaded and enhanced
NEWS	8	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS	9	NOV 24	MSDS-CCOHS file reloaded
NEWS	10	DEC 08	CABA reloaded with left truncation
NEWS	11	DEC 08	IMS file names changed
NEWS	12	DEC 09	Experimental property data collected by CAS now available in REGISTRY
NEWS	13	DEC 09	STN Entry Date available for display in REGISTRY and CA/CAPLUS
NEWS	14	DEC 17	DGENE: Two new display fields added
NEWS	15	DEC 18	BIOTECHNO no longer updated
NEWS	16	DEC 19	CROPU no longer updated; subscriber discount no longer available
NEWS	17	DEC 22	Additional INPI reactions and pre-1907 documents added to CAS databases
NEWS	18	DEC 22	IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS	19	DEC 22	ABI-INFORM now available on STN
NEWS	20	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS	21	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAPLUS
NEWS	22	FEB 05	German (DE) application and patent publication number format changes
NEWS	23	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS	24	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	25	MAR 03	FRANCEPAT now available on STN
NEWS EXPRESS			MARCH 5 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 3 MARCH 2004
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:33:14 ON 12 MAR 2004

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 10:33:47 ON 12 MAR 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 10 MAR 2004 HIGHEST RN 661450-61-9

DICTIONARY FILE UPDATES: 10 MAR 2004 HIGHEST RN 661450-61-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>


Uploading c:\program files\stnexp\queries\09869668.1

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 O, OH, MeO, EtO, n-PrO, i-PrO, n-BuO, i-BuO, s-BuO, t-BuO, X
 G2 CF3, C(O)CH3
 G3 CH, Cb

Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 10:34:19 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 17055 TO ITERATE

5.9% PROCESSED 1000 ITERATIONS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 333286 TO 348914
 PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s 11 sss full

FULL SEARCH INITIATED 10:34:30 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 343745 TO ITERATE

100.0% PROCESSED 343745 ITERATIONS
 SEARCH TIME: 00.00.11

2 ANSWERS

L3 2 SEA SSS FUL L1

=> file marpat

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

155.84

156.05

FILE 'MARPAT' ENTERED AT 10:34:49 ON 12 MAR 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Patel

<3/12/2004>

COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE CONTENT: 1988-PRESENT (VOL 140 ISS 10) (20040307/ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 6683216 27 JAN 2004
DE 10317487 12 FEB 2004
EP 1388563 11 FEB 2004
JP 2004047131 12 FEB 2004
WO 2004011964 05 FEB 2004

Structure search limits have been raised. See HELP SLIMIT for the new,
higher limits.

=> s ll sss full

FULL SEARCH INITIATED 10:35:18 FILE 'MARPAT'

FULL SCREEN SEARCH COMPLETED - 70092 TO ITERATE

8.3% PROCESSED	5836 ITERATIONS	(1 INCOMPLETE)	1 ANSWERS
11.9% PROCESSED	8339 ITERATIONS	(3 INCOMPLETE)	3 ANSWERS
21.7% PROCESSED	15225 ITERATIONS	(6 INCOMPLETE)	8 ANSWERS
28.0% PROCESSED	19632 ITERATIONS	(14 INCOMPLETE)	16 ANSWERS
33.8% PROCESSED	23702 ITERATIONS	(22 INCOMPLETE)	24 ANSWERS
40.8% PROCESSED	28566 ITERATIONS	(36 INCOMPLETE)	39 ANSWERS
47.1% PROCESSED	33045 ITERATIONS	(44 INCOMPLETE)	47 ANSWERS
54.2% PROCESSED	37970 ITERATIONS	(55 INCOMPLETE)	58 ANSWERS
59.4% PROCESSED	41651 ITERATIONS	(62 INCOMPLETE)	65 ANSWERS
65.4% PROCESSED	45833 ITERATIONS	(73 INCOMPLETE)	76 ANSWERS
70.4% PROCESSED	49356 ITERATIONS	(81 INCOMPLETE)	84 ANSWERS
75.2% PROCESSED	52680 ITERATIONS	(95 INCOMPLETE)	98 ANSWERS
79.1% PROCESSED	55444 ITERATIONS	(106 INCOMPLETE)	109 ANSWERS
81.5% PROCESSED	57097 ITERATIONS	(111 INCOMPLETE)	114 ANSWERS
82.6% PROCESSED	57914 ITERATIONS	(115 INCOMPLETE)	118 ANSWERS
84.1% PROCESSED	58954 ITERATIONS	(122 INCOMPLETE)	125 ANSWERS
85.0% PROCESSED	59580 ITERATIONS	(122 INCOMPLETE)	125 ANSWERS
85.4% PROCESSED	59879 ITERATIONS	(123 INCOMPLETE)	126 ANSWERS
85.6% PROCESSED	60000 ITERATIONS	(123 INCOMPLETE)	126 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.05.13

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 70092 TO 70092
PROJECTED ANSWERS: 126 TO 183

L4 126 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
113.20	269.25

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 10:40:39 ON 12 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Mar 2004 VOL 140 ISS 12
FILE LAST UPDATED: 11 Mar 2004 (20040311/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 10:33:14 ON 12 MAR 2004)

FILE 'REGISTRY' ENTERED AT 10:33:47 ON 12 MAR 2004

L1 STRUCTURE UPLOADED
L2 0 S L1
L3 2 S L1 SSS FULL

FILE 'MARPAT' ENTERED AT 10:34:49 ON 12 MAR 2004

L4 126 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 10:40:39 ON 12 MAR 2004

=> d l3 fbib hitstr abs total

YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:y

'FBIB' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

'HITSTR' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'
'ABS' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

The following are valid formats:

Substance information can be displayed by requesting individual fields or predefined formats. The predefined substance formats are: (RN = CAS Registry Number)

REG - RN
SAM - Index Name, MF, and structure - no RN
FIDE - All substance data, except sequence data
IDE - FIDE, but only 50 names
SQIDE - IDE, plus sequence data
SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used
SQD - Protein sequence data, includes RN
SQD3 - Same as SQD, but 3-letter amino acid codes are used
SQN - Protein sequence name information, includes RN

CALC - Table of calculated properties
EPROP - Table of experimental properties
PROP - EPROP and CALC

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

ABS -- Abstract
APPS -- Application and Priority Information
BIB -- CA Accession Number, plus Bibliographic Data
CAN -- CA Accession Number
CBIB -- CA Accession Number, plus Bibliographic Data (compressed)
IND -- Index Data
IPC -- International Patent Classification
PATS -- PI, SO
STD -- BIB, IPC, and NCL

IABS --ABS, indented, with text labels
IBIB -- BIB, indented, with text labels
ISTD -- STD format, indented

OBIB ----- AN, plus Bibliographic Data (original)
OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations
SIBIB ----- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.

The MAX format is the same as ALL.


The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

HELP DFIELDS -- To see a complete list of individual display fields.

HELP FORMATS -- To see detailed descriptions of the predefined formats.
 ENTER DISPLAY FORMAT (IDE):ide


L3 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 282095-40-3 REGISTRY
 CN 1,2,3-Benzotriazine-3(4H)-butanoic acid, 4-oxo- α -[2-oxo-2-[4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]ethyl]- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C26 H20 F3 N3 O5
 SR CA
 LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 282095-22-1 REGISTRY
 CN 2H-Isoindole-2-butanoic acid, α -[2-[4'-(acetyloxy)[1,1'-biphenyl]-4-yl]-2-oxoethyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C28 H23 N O7
 SR CA
 LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caold
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
0.44	274.09

FILE 'CAOLD' ENTERED AT 10:41:42 ON 12 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s ll sss full

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 10:41:52 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 343745 TO ITERATE

100.0% PROCESSED 343745 ITERATIONS
SEARCH TIME: 00.00.13

2 ANSWERS

L5 2 SEA SSS FUL L1

L6 0 L5

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.42

430.35

FILE 'CAPLUS' ENTERED AT 10:42:11 ON 12 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the

American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Mar 2004 VOL 140 ISS 12
FILE LAST UPDATED: 11 Mar 2004 (20040311/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13

L7 2 L3

=> s 14

L8 126 L4

=> d 17 fbib hitstr abs total

L7 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:247168 CAPLUS
DN 134:266035

TI Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives
for the treatment of multiple sclerosis

IN Fahrig, Thomas; Haning, Helmut; Riedl, Bernd; Braeunlich, Gabriele;
Henning, Rolf

PA Bayer Aktiengesellschaft, Germany

SO PCT Int. Appl., 116 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001022951	A2	20010405	WO 2000-EP8890	20000912
	WO 2001022951	A3	20011011		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
				GB 1999-22710	A 19990924
EP	1217994	A2	20020703	EP 2000-965974	20000912
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, IE, SI, LT, LV, FI, RO, MK, CY, AL			
				GB 1999-22710	A 19990924
				WO 2000-EP8890	W 20000912
	JP 2003510272	T2	20030318	JP 2001-526163	20000912
				GB 1999-22710	A 19990924
				WO 2000-EP8890	W 20000912
OS	MARPAT 134:266035				
IT	282095-22-1P 282095-40-3P				

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-biarylbutyric and 5-biarylpentanoic acid derivs. for the treatment of multiple sclerosis)


RN 282095-22-1 CAPLUS

CN 2H-Isoindole-2-butanoic acid, α -[2-[4'-(acetyloxy)[1,1'-biphenyl]-4-yl]-2-oxoethyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)



RN 282095-40-3 CAPLUS

CN 1,2,3-Benzotriazine-3(4H)-butanoic acid, 4-oxo- α -[2-oxo-2-[4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]ethyl]- (9CI) (CA INDEX NAME)



AB The title compds. (T)_xA-B-D-E-CO₂H [I, A = aryl, heteroaryl; B = aryl, heteroaryl, bond; each T is a substituent group; x = 0, 1, or 2; D = CO, CH(OH); E = two or three carbon chain bearing one to three substituent groups which are independent or are involved in ring formation], useful for the treatment of multiple sclerosis, were prepared E.g., (rac)-2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl]-4-(4'-ethoxy[1,1'-biphenyl]-4-yl)-4-oxobutanoic acid was prepared Inhibitory activities of I against matrix metalloproteases was determined

L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2000:475626 CAPLUS

DN 133:89429

TI Preparation of 4-aryl-4-oxo-2-(2-phthalimidoethyl)butanoates and analogs as matrix metalloprotease inhibitors

IN Fitzgerald, Mary F.; Gardiner, Philip J.; Nash, Kevin; Sturton, Graham; Benz, Gunter; Henning, Rolf; Schlemmer, Karl-Heinz; Riedl, Bernd; Haning, Helmut

PA Bayer Aktiengesellschaft, Germany

SO PCT Int. Appl., 146 pp.

CODEN: PIXXD2


DT Patent

LA English


FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----


PI WO 2000040539 A1 20000713 WO 1999-EP10110 19991220
 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 GB 1998-28845 A 19981230
 GB 1999-22709 A 19990924
 CA 2356053 AA 20000713 CA 1999-2356053 19991220
 GB 1998-28845 A 19981230
 GB 1999-22709 A 19990924
 WO 1999-EP10110W 19991220
 EP 1140768 A1 20011010 EP 1999-963582 19991220
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
 GB 1998-28845 A 19981230
 GB 1999-22709 A 19990924
 WO 1999-EP10110W 19991220
 BR 9916669 A 20011016 BR 1999-16669 19991220
 GB 1998-28845 A 19981230
 GB 1999-22709 A 19990924
 WO 1999-EP10110W 19991220
 JP 2002534404 T2 20021015 JP 2000-592250 19991220
 GB 1998-28845 A 19981230
 GB 1999-22709 A 19990924
 WO 1999-EP10110W 19991220
 ZA 2001004651 A 20020607 ZA 2001-4651 20010607
 GB 1998-28845 A 19981230
 OS MARPAT 133:89429
 IT **282095-22-1P 282095-40-3P**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 4-aryl-4-oxo-2-(2-phthalimidoethyl)butanoates and analogs as matrix metalloprotease inhibitors)
 RN 282095-22-1 CAPLUS
 CN 2H-Isoindole-2-butanoic acid, α -[2-[4'-(acetyloxy)[1,1'-biphenyl]-4-yl]-2-oxoethyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)



RN 282095-40-3 CAPLUS
 CN 1,2,3-Benzotriazine-3(4H)-butanoic acid, 4-oxo- α -[2-oxo-2-[4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]ethyl]- (9CI) (CA INDEX NAME)



GI



II

AB RZZ1Z2CO2H [I; R = (un)substituted Ph or -heteroaryl; Z = bond, (un)substituted 1,4-phenylene, -heteroarylene; Z1 = CO, CH(OH), C(:NOH), etc.; Z2 = substituted (CH2)2-3] were prepared Thus, di-tert-Bu 2-(2-phthalimidoethyl)malonate was condensed with 4-(EtO)C6H4C6H4(COCH2Br)-4 (preparation each given) and the saponified product mono-decarboxylated to give

title compound II. Data for biol. activity of I were given.

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 10:33:14 ON 12 MAR 2004)

FILE 'REGISTRY' ENTERED AT 10:33:47 ON 12 MAR 2004

L1 STRUCTURE UPLOADED

L2 0 S L1

L3 2 S L1 SSS FULL

FILE 'MARPAT' ENTERED AT 10:34:49 ON 12 MAR 2004

L4 126 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 10:40:39 ON 12 MAR 2004

FILE 'REGISTRY' ENTERED AT 10:41:17 ON 12 MAR 2004

FILE 'CAPLUS' ENTERED AT 10:41:24 ON 12 MAR 2004

FILE 'CAOLD' ENTERED AT 10:41:42 ON 12 MAR 2004

S L1

FILE 'REGISTRY' ENTERED AT 10:41:51 ON 12 MAR 2004
L5 2 S L1 SSS FULL

FILE 'CAOLD' ENTERED AT 10:42:04 ON 12 MAR 2004
L6 0 S L5 SSS FULL

FILE 'CAPLUS' ENTERED AT 10:42:11 ON 12 MAR 2004
L7 2 S L3
L8 126 S L4

=> s respiratory disease and 1,1'-buphenyl
MISMATCHED QUOTE '1,1'-BUPHENYL'
Quotation marks (or apostrophes) must be used in pairs,
one before and one after the expression you are setting
off or masking.

=> s respiratory disease and phenyl
L9 48 RESPIRATORY DISEASE AND PHENYL

=> s respiratory disease and 1,1'-biphenyl
MISMATCHED QUOTE '1,1'-BIPHENYL'
Quotation marks (or apostrophes) must be used in pairs,
one before and one after the expression you are setting
off or masking.

=> s respiratory disease and biphenyl
L10 8 RESPIRATORY DISEASE AND BIPHENYL

=> s l7 and l8
L11 2 L7 AND L8

=> s l8 and respiratory diseases
L12 0 L8 AND RESPIRATORY DISEASES

=> s l9 and l10
L13 4 L9 AND L10

=> s l8 and l13
L14 0 L8 AND L13

=> s l8 and l10
L15 0 L8 AND L10

=> d l13 fbib hitstr abs total



L13 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:242154 CAPLUS
DN 138:254964
TI Preparation of 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenols as
selective β 2-adrenoreceptor agonists for treatment of
respiratory diseases
IN Box, Philip Charles; Coe, Diane Mary; Looker, Brian Edgar; Procopiou,
Panayiotis Alexandrou
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 117 pp.
CODEN: PIXXD2
DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003024439	A1	20030327	WO 2002-GB4140	20020911
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				GB 2001-22201	A 20010914
				GB 2001-26997	A 20011109

OS MARPAT 138:254964
GI



AB Title phenethanolamines I [wherein $m = 2-8$, $n = 2-5$; and $m + n = 4-10$; $R_1 = H$, (halo)alkyl, OH, halo, XCONR₉R₁₀, XNR₈COR₉, XNR₈CONR₉R₁₀, XNR₈SO₂R₉, XSO₂NR₁₁R₁₂, XNR₈SO₂NR₉R₁₀, XNR₉R₁₀, XN+R₈R₉R₁₀, XNR₈CO₂R₉, XCO₂R₉, XNR₈CONR₈CONR₉R₁₀, XSR₉, XSOR₉, XSO₂R₉, or (un)substituted X-(hetero)aryl, or X-aryloxy; R_2 and $R_3 =$ independently H, OH, (halo)alkyl, (halo)alkoxy, halo, or aryl(alkyl); R_4 and $R_5 =$ independently H or alkyl with the proviso that the total number of C atoms in R_4 and $R_5 \leq 4$; R_6 and $R_7 =$ independently H or alkyl with the proviso that the total number of C atoms in R_6 and $R_7 \leq 4$; $X = (CH_2)_p$ or alkenylene; $p = 0-6$; R_8 and $R_9 =$ independently H, or (un)substituted (cyclo)alkyl, (hetero)aryl, or (hetero)arylalkyl; $R_{10} = H$ or (cyclo)alkyl; R_{11} and $R_{12} =$ independently H, (cyclo)alkyl, (hetero)aryl, or (hetero)arylalkyl; or NR₁₁R_{12} = (un)substituted heterocyclyl; with addnl. provisos; or salts, solvates, or}

physiol. functional derivs. thereof] were prepared as selective stimulants of β 2-adrenoceptors. For example, coupling of (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one with [2-[(6-bromohexyl)oxy]ethoxy](tert-butyl)dimethylsilane using NaH in DMF (preparation of starting materials given), deprotection of the alc. with Bu₄NF in THF, etherification with 3-nitrobenzyl bromide in DMF in the presence of NaH, and hydrogenation over platinum oxide afforded (5R)-3-[6-[2-[(3-aminobenzyl)oxy]ethoxy]hexyl]-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one. Reaction of the amine with PhNCO in i-PrOH to give the urea, ring opening using Me₃SiOK in THF, and hydrolysis with AcOH and H₂O provided (R)-II•AcOH. The latter exhibited β 2-adrenoreceptor agonist activity with IC₅₀ values < 1 μ M and showed five fold selectivity for the β 2- over β 3-adrenoceptors. Elec.- or spasmogen-induced contractions in human or guinea pig airway tissue were typically suppressed by preferred compds. of the invention in < 30 min and maintained for > 3 h. Thus, I are useful for the prophylaxis and treatment of **respiratory diseases**.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:658074 CAPLUS

DN 137:201142

TI Preparation of 2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)**phenyl**]
]ethanamine derivatives as β 2-adrenoreceptor agonists for treatment
of **respiratory diseases**

IN Biggadike, Keith; Coe, Diane Mary; Edney, Dean David; Halton, Abigail;
Looker, Brian Edgar; Monteith, Michael John; Moore, Rebecca Jane; Patel,
Rajnikant; Procopiou, Panayiotis Alexandrou

PA Glaxo Group Limited, UK

SO PCT Int. Appl., 88 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002066422	A1	20020829	WO 2002-EP1387	20020211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			GB 2001-3630	A 20010214
			GB 2001-26998	A 20011109
EP 1360174	A1	20031112	EP 2002-706735	20020211
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			GB 2001-3630	A 20010214
			GB 2001-26998	A 20011109
			WO 2002-EP1387	W 20020211
NO 2003003594	A	20031002	NO 2003-3594	20030813


GB 2001-3630 A 20010214

GB 2001-26998 A 20011109


WO 2002-EP1387 W 20020211

OS MARPAT 137:201142

GI



I



II

AB The title phenethanolamines I [wherein $m = 2-8$; $n = 3-11$; with the proviso the $m + n = 5-19$; $R1 = XSO_2NR_6R_7$; $R2$ and $R3 =$ independently H, (halo)alkyl, alkoxy, halo, or Ph; $R4$ and $R5 =$ independently H or alkyl with the proviso that the total number of C's in $R4$ and $R5 \leq 4$; $X = (CH_2)_p$ or alkenylene; $p = 0-6$; $R6$ and $R7 =$ independently H, $CONR_8R_9$, or (un)substituted (cyclo)alkyl, Ph, or phenylalkyl; or $NR_6R_7 =$ (un)substituted N-containing ring; $R8$ and $R9 =$ independently H, (cyclo)alkyl, Ph, or phenylalkyl; or salts, solvates, or physiol. functional derivs. thereof] were prepared as β_2 -adrenoreceptor agonists. For example, (R)-II•AcOH was synthesized in ten steps beginning with the coupling of di-*t*-Bu iminodicarboxylate with 2-bromo-1-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)ethanone in the presence of Cs_2CO_3 in AcCN. Forty-nine compds. of the invention displayed agonist activity against human β_2 -adrenoreceptors with IC_{50} values below $1 \mu M$. Thus, I and pharmaceutical compns. containing them are useful in the prophylaxis and treatment of **respiratory diseases** (no data).

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:391690 CAPLUS

DN 136:386115

TI Substituted 2-phenylaminoimidazoline **phenyl** ketone derivatives as human platelet IP receptor antagonists

IN Jahangir, Alam



PA F. Hoffmann-La Roche Ag, Switz.

SO PCT Int. Appl., 59 pp.

CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002040453	A1	20020523	WO 2001-EP12776	20011105
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2002021808	A5	20020527	US 2000-248888PP	20001114
				AU 2002-21808	20011105
				US 2000-248888PP	20001114
	BR 2001015291	A	20030819	WO 2001-EP12776W	20011105
				BR 2001-15291	20011105
				US 2000-248888PP	20001114
	EP 1339694	A1	20030903	WO 2001-EP12776W	20011105
				EP 2001-996531	20011105
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
				US 2000-248888PP	20001114
	US 6417186	B1	20020709	WO 2001-EP12776W	20011105
	US 2002091147	A1	20020711	US 2001-14110	20011113
				US 2000-248888PP	20001114
	NO 2003002142	A	20030513	NO 2003-2142	20030513
				US 2000-248888PP	20001114
				WO 2001-EP12776W	20011105
OS	MARPAT 136:386115				
GI					



AB Title compds. I [] were prepared For instance, 4-fluoroacetophenone and 4-nitrobenzaldehyde were reacted together (EtOHaq, KOH) to give 1-[4-fluorophenyl]-3-[4-nitrophenyl]propenone. This intermediate was reduced (EtOAc, H₂-10% Pd/C) and reacted with 2-chloro-4,5-dihydro-1H-imidazole sulfate to give II in 54.2% overall yield. Example compds. had pK_i in the range of 7.1 to 9.6 for the human platelet IP receptor; II had pK_i = 9.50. I are used for the treatment of diseases associated with pain, inflammation, urinary tract disease states, **respiratory disease** states, edema formation, or hypotensive vascular diseases.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:693269 CAPLUS
DN 135:257467
TI Preparation of N-(arylmethoxycarbonyl)phenylalanine derivatives as IP antagonists
IN Cournoyer, Richard Leo; Keitz, Paul Francis; Lowrie, Lee Edwin, Jr.; Muehldorf, Alexander Victor; O'Yang, Counde; Yasuda, Dennis Mitsugu
PA F. Hoffmann-La Roche A.-G., Switz.
SO PCT Int. Appl., 100 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1



	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001068591	A1	20010920	WO 2001-EP2597	20010308
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
				US 2000-190129PP	20000316
				US 2000-247129PP	20001110
	BR 2001009235	A	20021217	BR 2001-9235	20010308
				US 2000-190129PP	20000316
				US 2000-247129PP	20001110
				WO 2001-EP2597 W	20010308
	EP 1265853	A1	20021218	EP 2001-925395	20010308
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
				US 2000-190129PP	20000316
				US 2000-247129PP	20001110
				WO 2001-EP2597 W	20010308
	JP 2003527368	T2	20030916	JP 2001-567688	20010308
				US 2000-190129PP	20000316
				US 2000-247129PP	20001110
				WO 2001-EP2597 W	20010308
	US 2001056100	A1	20011227	US 2001-810436	20010314
	US 6693098	B2	20040217		
				US 2000-190129PP	20000316

NO 2002004387 A 20021021

US 2003220367 A1 20031127

US 2000-247129PP 20001110
 NO 2002-4387 20020913
 US 2000-190129PP 20000316
 US 2000-247129PP 20001110
 WO 2001-EP2597 W 20010308
 US 2003-434809 20030509
 US 2000-190129PP 20000316
 US 2000-247129PP 20001110
 US 2001-810436 A320010314

OS MARPAT 135:257467
 GI



AB Title compds. I [wherein R1, R2, and R3 = independently (un)substituted (hetero)aryl; R4 = COOH or tetrazolyl; A = single bond, O(CH2)q, S(CH2)q, NR'(CH2)q, (CH2)qO, O(CH2)qO, (CH2)qO(CH2)q, (CH2)nCO(CH2)q, CONH, (CH2)q, CH:CH, or C.tplbond.C; R' = H or alkyl; B = (CH2)r, CH2O, CH2OCH2, or CH2NH; m, q, and r = independently 1-3; n and p = independently 0-3; or individual isomers, racemic or nonracemic mixts. of isomers, or pharmaceutically acceptable salts or solvates thereof] were prepared as prostaglandin IP receptor antagonists. For example, 4-vinylbenzoic acid was esterified with MeOH (97.4%). The ester was hydroborated with 9-BBN in THF and oxidized with alkaline HOOH to give 4-(2-hydroxyethyl)benzoic acid Me ester (64.7%). Etherification with PhOH in the presence of PPh3 and diEt azodicarboxylate in THF (16.8%), followed by reduction with LiAlH4, condensation with Me (R)-2-isocyanato-3-phenylpropionate, and hydrolysis, afforded II. The latter showed affinity toward the human platelet IP receptor with a Ki value of 6.6. I are useful for the treatment of inflammatory conditions, pain, bladder disorders, hypotensive vascular diseases, and **respiratory diseases**, such as allergies and asthma (no data).

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 10:33:14 ON 12 MAR 2004)

FILE 'REGISTRY' ENTERED AT 10:33:47 ON 12 MAR 2004

L1 STRUCTURE UPLOADED

L2 0 S L1

L3 2 S L1 SSS FULL

FILE 'MARPAT' ENTERED AT 10:34:49 ON 12 MAR 2004

L4 126 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 10:40:39 ON 12 MAR 2004

FILE 'REGISTRY' ENTERED AT 10:41:17 ON 12 MAR 2004

FILE 'CAPLUS' ENTERED AT 10:41:24 ON 12 MAR 2004

FILE 'CAOLD' ENTERED AT 10:41:42 ON 12 MAR 2004
S L1

FILE 'REGISTRY' ENTERED AT 10:41:51 ON 12 MAR 2004

L5 2 S L1 SSS FULL

FILE 'CAOLD' ENTERED AT 10:42:04 ON 12 MAR 2004

L6 0 S L5 SSS FULL

FILE 'CAPLUS' ENTERED AT 10:42:11 ON 12 MAR 2004

L7 2 S L3

L8 126 S L4

L9 48 S RESPIRATORY DISEASE AND PHENYL

L10 8 S RESPIRATORY DISEASE AND BIPHENYL

L11 2 S L7 AND L8

L12 0 S L8 AND RESPIRATORY DISEASES

L13 4 S L9 AND L10

L14 0 S L8 AND L13

L15 0 S L8 AND L10

=> s l8 and indilinine

L16 0 L8 AND INDILINONE

=> s l8 and inimidazolidinone

L17 0 L8 AND INMIDAZOLIDINONE

=> s l8 and imidazolidinone

L18 0 L8 AND IMIDAZOLIDINONE

=> s l8 and phtahlazine

L19 0 L8 AND PHTAHLAZINE

=> s l8 and asthma

L20 8 L8 AND ASTHMA

=> s l8 and ARDS

L21 0 L8 AND ARDS

=> a l8 and TNF alpha

A IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l8 and TNF alpha

L22 2 L8 AND TNF ALPHA

=> s l6 and rhinitis

L23 0 L6 AND RHINITIS

=> s l8 and bronchiectasis

L24 0 L8 AND BRONCHIECTASIS

=> s l8 and silicosis

L25 0 L8 AND SILICOSIS

=> s silicosis and bronchiectasis

L26 15 SILICOSIS AND BRONCHIECTASIS

=> s l16 and l8

L27 0 L16 AND L8

=> s l26 and asthma

L28 11 L26 AND ASTHMA

=> d his

(FILE 'HOME' ENTERED AT 10:33:14 ON 12 MAR 2004)

FILE 'REGISTRY' ENTERED AT 10:33:47 ON 12 MAR 2004

L1 STRUCTURE UPLOADED

L2 0 S L1

L3 2 S L1 SSS FULL

FILE 'MARPAT' ENTERED AT 10:34:49 ON 12 MAR 2004

L4 126 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 10:40:39 ON 12 MAR 2004

FILE 'REGISTRY' ENTERED AT 10:41:17 ON 12 MAR 2004

FILE 'CAPLUS' ENTERED AT 10:41:24 ON 12 MAR 2004

FILE 'CAOLD' ENTERED AT 10:41:42 ON 12 MAR 2004

S L1

FILE 'REGISTRY' ENTERED AT 10:41:51 ON 12 MAR 2004

L5 2 S L1 SSS FULL

FILE 'CAOLD' ENTERED AT 10:42:04 ON 12 MAR 2004

L6 0 S L5 SSS FULL

FILE 'CAPLUS' ENTERED AT 10:42:11 ON 12 MAR 2004

L7 2 S L3

L8 126 S L4

L9 48 S RESPIRATORY DISEASE AND PHENYL